Glutathione Reconstitution Calculator

No. Glutathione (GSH) is not an FDA-approved drug; it is sold as a dietary supplement, and injectable forms are compounded for off-label clinical use (practitioner consensus). It has nonetheless been studied in randomized controlled human trials: intravenous GSH (1.5 g/m²) reduced oxaliplatin-induced neurotoxicity in colorectal cancer patients without impairing antitumor activity (RCT). Injectable glutathione is pharmacologically well-characterized but regulated as a compounded preparation, not an approved therapeutic.

Injectable (IV/IM) delivers the drug directly into plasma, bypassing intestinal degradation by γ-glutamyl transferase, and is the only route validated in a chemotherapy RCT (RCT). Plain oral GSH has poor bioavailability because it is broken down in the gut [4,5]. In a crossover trial of people with metabolic syndrome, sublingual GSH raised plasma total and reduced GSH and the GSH/GSSG ratio significantly more than oral GSH or NAC (RCT). Oral liposomal GSH maintained whole-blood GSH levels and reduced oxidative stress over 3 months in type 2 diabetics, who are typically GSH-deficient (RCT). Rank order for raising plasma GSH: IV/IM > sublingual/liposomal > plain oral.

There are no human pregnancy or lactation data for glutathione supplementation, and injectable use in pregnancy has never been studied (practitioner consensus). GSH is an endogenous molecule whose amino-acid precursors are normal dietary constituents, but non-essential supplementation during pregnancy and breastfeeding is not recommended (practitioner consensus). Individuals with active cancer should consult their oncologist before supplementing: tumor cells exploit elevated GSH for antioxidant defense, proliferation, and chemotherapy resistance (mechanistic, review) [8,13].

Chronic or cyclical use is typical, since GSH levels decline with aging and low GSH is associated with neurodegenerative and metabolic disease (review, observational) [4,9]. The longest controlled human protocol is 3 months of daily oral liposomal GSH, which was well tolerated with no safety signals (RCT). For injectables, common practice is 8–12 week cycles with breaks rather than indefinite continuous use (community protocol). The GSH precursor NAC has been used as a durable GSH-restoring strategy in aged animals, where it reversed age-related loss of synaptic plasticity (animal).

NAC is a cysteine prodrug and NRF2 activator that supports endogenous GSH synthesis, with more reliable oral absorption than plain oral GSH (review). Direct human comparison favors sublingual GSH: it increased plasma total GSH and the GSH/GSSG ratio more than NAC at matched dosing (RCT). γ-Glutamylcysteine (GGC), the immediate GSH precursor, outperformed both NAC and GSH for restoring GSH and suppressing inflammation in a mouse sepsis model (animal), and GGC restored GSH and reduced oxidative and inflammatory markers in Aβ-treated human astrocytes (in-vitro). In practice, NAC is the cheapest oral option; sublingual/liposomal GSH and GGC offer more direct GSH elevation.

Yes. Reduced glutathione oxidizes readily to the disulfide (GSSG) in solution; compounded vials should be refrigerated at 2–8°C, protected from light, and used promptly after reconstitution (practitioner consensus). Oxidation is visible as cloudiness, color change, or sulfur odor. Discard if present. Air travel with compounded injectables in carry-on is generally permitted with prescription labeling, a cooler pack, and documentation from the prescribing clinic (practitioner consensus). Oral liposomal and sublingual forms are room-temperature stable but should stay sealed and dry.

Oral liposomal GSH: ~500–1000 mg/day (practitioner consensus), used for 3 months in a clinical trial (RCT). Sublingual GSH: studied at proprietary milligram doses producing plasma GSH increases; practitioner ranges are 50–100 mg/day (RCT; community protocol). Intravenous: 1.5 g/m² body surface area (~2.5–3 g for a 70 kg adult) immediately before each oxaliplatin cycle (practitioner consensus); common wellness-infusion dosing is 600–1400 mg per session (practitioner consensus). Intramuscular: 600–1200 mg, 1–2 times weekly (community protocol). Intramuscular injections have no published human pharmacokinetic data; dosing derives from clinical extrapolation (practitioner consensus).

Cancer is a legitimate concern: GSH and its enzyme systems protect tumor cells from oxidative stress and underpin chemotherapy resistance (mechanistic, review) [8,13]. However, the only RCT of IV GSH during active chemotherapy found no impairment of antitumor efficacy (RCT), so the clinical risk is unresolved rather than proven. On exercise: glutamine supplementation that augments the glutamine–GSH axis supported muscle heat-shock-protein response in resistance-trained rats (animal) [10,11], and combined L-citrulline + GSH increased post-exercise nitric-oxide markers in resistance-trained men (RCT). There is no evidence GSH blunts training adaptations; available data suggest it supports recovery signaling.